GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » Sloan Ratio %

Oyster Point Pharma (Oyster Point Pharma) Sloan Ratio % : 0.00% (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Oyster Point Pharma's Sloan Ratio for the quarter that ended in Sep. 2022 was 0.00%.

As of Sep. 2022, Oyster Point Pharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Oyster Point Pharma Sloan Ratio % Historical Data

The historical data trend for Oyster Point Pharma's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oyster Point Pharma Sloan Ratio % Chart

Oyster Point Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Sloan Ratio %
- - -3.28 -5.77 -4.40

Oyster Point Pharma Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.28 -4.40 -3.32 -11.15 -

Competitive Comparison of Oyster Point Pharma's Sloan Ratio %

For the Biotechnology subindustry, Oyster Point Pharma's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oyster Point Pharma's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Oyster Point Pharma's Sloan Ratio % falls into.



Oyster Point Pharma Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Oyster Point Pharma's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2021 )-Cash Flow from Operations (A: Dec. 2021 )
-Cash Flow from Investing (A: Dec. 2021 ))/Total Assets (A: Dec. 2021 )
=(-100.659--89.37
--1.485)/222.617
=-4.40%

Oyster Point Pharma's Sloan Ratio for the quarter that ended in Sep. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2022 )
=(-176.645--165.995
--0.438)/109.201
=-9.35%

Oyster Point Pharma's Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was -42.064 (Dec. 2021 ) + -47.892 (Mar. 2022 ) + -49.942 (Jun. 2022 ) + -36.747 (Sep. 2022 ) = $-176.65 Mil.
Oyster Point Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2022 was -41.489 (Dec. 2021 ) + -49.705 (Mar. 2022 ) + -38.83 (Jun. 2022 ) + -35.971 (Sep. 2022 ) = $-166.00 Mil.
Oyster Point Pharma's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2022 was -0.235 (Dec. 2021 ) + -0.085 (Mar. 2022 ) + -0.118 (Jun. 2022 ) + 0 (Sep. 2022 ) = $-0.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oyster Point Pharma  (NAS:OYST) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2022, Oyster Point Pharma has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Oyster Point Pharma Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oyster Point Pharma (Oyster Point Pharma) Business Description

Traded in Other Exchanges
N/A
Address
202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540
Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
Executives
Ozawa Clare director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades director C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko officer: Chief Commercial Officer C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c. director, 10 percent owner 126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau director, officer: President and CEO 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner officer: Chief Financial Officer 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p. director, 10 percent owner 126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022

Oyster Point Pharma (Oyster Point Pharma) Headlines